Conjugates of daidzein-alliinase as a targeted pro-drug enzyme system against ovarian carcinoma

Journal of Drug Targeting

Volumn 19, Issue 5, 2011, Pages 326-335

  Appel, Elena ^a   Rabinkov, Aharon ^a   Neeman, Michal ^a   Kohen, Fortune ^a   Mirelman, David ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

allicin; alliin; Alliinase; daidzein; drug targeting; ovarian carcinoma

Indexed keywords

ALLIIN; ANTINEOPLASTIC AGENT; DAIDZEIN ALLIINASE CYTE 777; DAIDZEIN ALLIINASE EUROPIUM; DAIDZEIN ALLIINASE FUSION PROTEIN; HYBRID PROTEIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BINDING AFFINITY; BIOLUMINESCENCE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; ENZYME PRODRUG THERAPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; TARGET CELL DESTRUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBON-SULFUR LYASES; CELL LINE, TUMOR; CELL SURVIVAL; CYSTEINE; DRUG COMPOUNDING; FEMALE; FLUORESCENT DYES; HUMANS; ISOFLAVONES; LUCIFERASES; MICE; MICE, NUDE; MOLECULAR IMAGING; OVARIAN NEOPLASMS; PRODRUGS; TISSUE DISTRIBUTION; TRANSFECTION; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955608879     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2010.504265     Document Type: Article

References (44)

1. Aggarwal BB, Shishodia S. (2006). Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol, 71, 1397-1421.
2. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M, Visintin I, Mor G. (2009). Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle, 8, 158-166.
3. Appel E, Vallon-Eberhard A, Rabinkov A, Brenner O, Shin I, Sasson K, Shadkchan Y, Osherov N, Jung S, Mirelman D. (2010). Therapy of murine pulmonary aspergillosis with antibody-alliinase conjugates and alliin. Antimicrob Agents Chemother, 54, 898-906.
4. Apte SM, Fan D, Killion JJ, Fidler IJ. (2004). Targeting the plateletderived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res, 10, 897-908. (Pubitemid 38198888)
5. Arditti FD, Rabinkov A, Miron T, Reisner Y, Berrebi A, Wilchek M, Mirelman D. (2005). Apoptotic killing of B-chronic lymphocytic leukemia tumor cells by allicin generated in situ using a rituximaballiinase conjugate. Mol Cancer Ther, 4, 325-331. (Pubitemid 40340211)
6. Barnes S, Sfakianos J, Coward L, Kirk M. (1996). Soy isoflavonoids and cancer prevention. Underlying biochemical and pharmacological issues. Adv Exp Med Biol, 401, 87-100. (Pubitemid 26326193)
7. Berchuck A, Elbendary A, Havrilesky L, Rodriguez GC, Bast RC Jr. (1994). Pathogenesis of ovarian cancers. J Soc Gynecol Investig, 1, 181-190. (Pubitemid 2134376)
8. Breidenbach M, Rein DT, Everts M, Glasgow JN, Wang M, Passineau MJ, Alvarez RD, Korokhov N, Curiel DT. (2005). Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther, 12, 187-193. (Pubitemid 40185922)
9. Campos SM, Ghosh S. (2010). A current review of targeted therapeutics for ovarian cancer. J Oncol, 2010, 149362.
10. de Vos FY, Bos AM, Gietema JA, Pras E, Van der Zee AG, de Vries EG, Willemse PH. (2004). Paclitaxel and carboplatin concurrent with radiotherapy for primary cervical cancer. Anticancer Res, 24, 345-348. (Pubitemid 38279730)
11. de Vos FY, Nuver J, Willemse PH, van der Zee AG, Messerschmidt J, Burgerhof JG, de Vries EG, Gietema JA. (2004). Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy; cardiovascular risk factors and signs of vascular damage. Eur J Cancer, 40, 696-700. (Pubitemid 38326619)
12. de Wilde A, Heberden C, Chaumaz G, Bordat C, Lieberherr M. (2006). Signaling networks from Gbeta1 subunit to transcription factors and actin remodeling via a membrane-located ERbeta-related protein in the rapid action of daidzein in osteoblasts. J Cell Physiol, 209, 786-801. (Pubitemid 44665701)
13. Erlanger BF, Borek F, Beiser SM, Lieberman S. (1957). Steroid-protein conjugates. I. Preparation and characterization of conjugates of bovine serum albumin with testosterone and with cortisone. J Biol Chem, 228, 713-727.
14. Fishman DA, Bozorgi K. (2002). The scientific basis of early detection of epithelial ovarian cancer: the National Ovarian Cancer Early Detection Program (NOCEDP). Cancer Treat Res, 107, 3-28.
15. Hilderbrand SA, Kelly KA, Weissleder R, Tung CH. (2005). Monofunctional near-infrared fluorochromes for imaging applications. Bioconjug Chem, 16, 1275-1281. (Pubitemid 41368131)
16. Hirsch K, Danilenko M, Giat J, Miron T, Rabinkov A, Wilchek M, Mirelman D, Levy J, Sharoni Y. (2000). Effect of purified allicin, the major ingredient of freshly crushed garlic, on cancer cell proliferation. Nutr Cancer, 38, 245-254. (Pubitemid 32762025)
17. Huang YH, Zugates GT, Peng W, Holtz D, Dunton C, Green JJ, Hossain N, Chernick MR, Padera RF Jr, Langer R, Anderson DG, Sawicki JA. (2009). Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice. Cancer Res, 69, 6184-6191.
18. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. (2006). Cancer statistics, 2006. CA Cancer J Clin, 56, 106-130.
19. Kohen F, Gayer B, Kulik T, Frydman V, Nevo N, Katzburg S, Limor R, Sharon O, Stern N, Somjen D. (2007). Synthesis and evaluation of the antiproliferative activities of derivatives of carboxyalkyl isoflavones linked to N-t-Boc-hexylenediamine. J Med Chem, 50, 6405-6410. (Pubitemid 350250427)
20. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA. (1998). Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology, 139, 4252-4263. (Pubitemid 28513713)
21. Lamartiniere CA, Wang J, Smith-Johnson M, Eltoum IE. (2002). Daidzein: bioavailability, potential for reproductive toxicity, and breast cancer chemoprevention in female rats. Toxicol Sci, 65, 228-238. (Pubitemid 34121115)
22. Landen CN, Kinch MS, Sood AK. (2005). EphA2 as a target for ovarian cancer therapy. Expert Opin Ther Targets, 9, 1179-1187. (Pubitemid 41762872)
23. Lehtonen JY, Adlercreutz H, Kinnunen PK. (1996). Binding of daidzein to liposomes. Biochim Biophys Acta, 1285, 91-100. (Pubitemid 26388757)
24. Migalovich HS, Kalchenko V, Nevo N, Meir G, Kohen F, Neeman M. (2009). Harnessing competing endocytic pathways for overcoming the tumor-blood barrier: magnetic resonance imaging and nearinfrared imaging of bifunctional contrast media. Cancer Res, 69, 5610-5617.
25. Miron T, Mironchik M, Mirelman D, Wilchek M, Rabinkov A. (2003). Inhibition of tumor growth by a novel approach: in situ allicin generation using targeted alliinase delivery. Mol Cancer Ther, 2, 1295-1301.
26. Miron T, Rabinkov A, Mirelman D, Weiner L, Wilchek M. (1998). A spectrophotometric assay for allicin and alliinase (Alliin lyase) activity: reaction of 2-nitro-5-thiobenzoate with thiosulfinates. Anal Biochem, 265, 317-325. (Pubitemid 29002078)
27. Miron T, Rabinkov A, Mirelman D, Wilchek M, Weiner L. (2000). The mode of action of allicin: its ready permeability through phospholipid membranes may contribute to its biological activity. Biochim Biophys Acta, 1463, 20-30. (Pubitemid 30019232)
28. Miron T, Shin I, Feigenblat G, Weiner L, Mirelman D, Wilchek M, Rabinkov A. (2002). A spectrophotometric assay for allicin, alliin, and alliinase (alliin lyase) with a chromogenic thiol: reaction of 4-mercaptopyridine with thiosulfinates. Anal Biochem, 307, 76-83.
29. Miron T, SivaRaman H, Rabinkov A, Mirelman D, Wilchek M. (2006). A method for continuous production of allicin using immobilized alliinase. Anal Biochem, 351, 152-154.
30. Miron T, Wilchek M, Sharp A, Nakagawa Y, Naoi M, Nozawa Y, Akao Y. (2008). Allicin inhibits cell growth and induces apoptosis through the mitochondrial pathway in HL60 and U937 cells. J Nutr Biochem, 19, 524-535.
31. Morgan RT, Woods LK, Moore GE, Quinn LA, McGavran L, Gordon SG. (1980). Human cell line (COLO 357) of metastatic pancreatic adenocarcinoma. Int J Cancer, 25, 591-598. (Pubitemid 10156843)
32. Prager-Khoutorsky M, Goncharov I, Rabinkov A, Mirelman D, Geiger B, Bershadsky AD. (2007). Allicin inhibits cell polarization, migration and division via its direct effect on microtubules. Cell Motil Cytoskeleton, 64, 321-337. (Pubitemid 46608667)
33. Rabinkov A, Miron T, Konstantinovski L, Wilchek M, Mirelman D, Weiner L. (1998). The mode of action of allicin: trapping of radicals and interaction with thiol containing proteins. Biochim Biophys Acta, 1379, 233-244. (Pubitemid 28252900)
34. Rabinkov A, Miron T, Mirelman D, Wilchek M, Glozman S, Yavin E, Weiner L. (2000). S-Allylmercaptoglutathione: the reaction product of allicin with glutathione possesses SH-modifying and antioxidant properties. Biochim Biophys Acta, 1499, 144-153.
35. Rabinkov A, Zhu XZ, Grafi G, Galili G, Mirelman D. (1994). Alliin lyase (Alliinase) from garlic (Allium sativum). Biochemical characterization and cDNA cloning. Appl Biochem Biotechnol, 48, 149-171.
36. Rofstad EK, Sutherland RM. (1989). Growth and radiation sensitivity of the MLS human ovarian carcinoma cell line grown as multicellular spheroids and xenografted tumours. Br J Cancer, 59, 28-35. (Pubitemid 19051306)
37. Schwartz PE. (2002). Current diagnosis and treatment modalities for ovarian cancer. Cancer Treat Res, 107, 99-118.
38. Shan K, Lincoff AM, Young JB. (1996). Anthracycline-induced cardiotoxicity. Ann Intern Med, 125, 47-58.
39. Shimon LJ, Rabinkov A, Shin I, Miron T, Mirelman D, Wilchek M, Frolow F. (2007). Two structures of alliinase from Alliium sativum L.: apo form and ternary complex with aminoacrylate reaction intermediate covalently bound to the PLP cofactor. J Mol Biol, 366, 611-625. (Pubitemid 46138105)
40. Somjen D, Katzburg S, Nevo N, Gayer B, Hodge RP, Renevey MD, Kalchenko V, Meshorer A, Stern N, Kohen F. (2008). A daidzeindaunomycin conjugate improves the therapeutic response in an animal model of ovarian carcinoma. J Steroid Biochem Mol Biol, 110, 144-149.
41. Somjen D, Kohen F, Lieberherr M, Gayer B, Schejter E, Katzburg S, Limor R, Sharon O, Knoll E, Posner GH, Kaye AM, Stern N. (2005). Membranal effects of phytoestrogens and carboxy derivatives of phytoestrogens on human vascular and bone cells: new insights based on studies with carboxy-biochanin A. J Steroid Biochem Mol Biol, 93, 293-303. (Pubitemid 40602503)
42. Starr AN, Vexler A, Marmor S, Konik D, Ashkenasi-Voghera M, Lev- Ari S, Greif Y, Ben-Yosef R. (2005). Establishment and characterization of a pancreatic carcinoma cell line derived from malignant pleural effusion. Oncology, 69, 239-245. (Pubitemid 41433582)
43. Tseng JC, Hurtado A, Yee H, Levin B, Boivin C, Benet M, Blank SV, Pellicer A, Meruelo D. (2004). Using sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models. Cancer Res, 64, 6684-6692. (Pubitemid 39297931)
44. Zeineldin R, Muller CY, Stack MS, Hudson LG. (2010). Targeting the EGF receptor for ovarian cancer therapy. J Oncol, 2010, 414676.